SANTA MONICA, Calif. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it has signed a Letter of Intent with the National Center for